Articles tagged with Immunotherapy
The UC San Diego Alpha Stem Cell Clinic will receive $8 million in funding to launch new clinical trials and improve accessibility of stem cell therapies. The clinic has already launched 59 clinical trials and treated 277 patients with various diseases.
Scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy by using natural killer (NK) cells. The research team developed a monoclonal antibody targeting KIR2DL5, which allowed NK cells to vigorously attack and shrink human tumors.
Researchers found histamine releases HMGB1 in vascular endothelial cells, leading to severe symptoms. Administering anti-HMGB1 antibody attenuated hypotension and improved recovery rates.
Researchers report a promising new approach that involves altering sugar molecules on the surface of cancer cells in mice, leading to a significant increase in anti-tumor immune response. The study focuses on sialic acid sugars, which are also present on healthy cells and play a role in cell-to-cell communication.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
A new approach to allergy treatment has shown promise in reducing symptoms of allergic rhinitis by 36% after just one year of treatment. The combination of a monoclonal antibody with cat allergy shots was found to be more effective than allergy shots alone in providing long-lasting symptom relief.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a way to overcome barriers limiting cancer immunotherapies. They discovered that activating the STING protein can increase regulatory B cells, which suppress anti-cancer immunity.
Stowers scientists investigate macrophage activation states in zebrafish sensory organ, discovering three distinct anti-inflammatory pathways that may inform human regenerative immunotherapies. The study provides valuable insights into the timing and genetic programs of macrophages, a type of white blood cell, in repair and regeneration.
Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
In an international clinical trial, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated and met its primary endpoint with a pathologic complete response rate of 50.6%.
Researchers at MUSC found that extracting and isolating Treg cells and transplanting them back into the same system successfully treats osteogenesis imperfecta for a year. The treatment results in stronger bones, increased osteoblast numbers, and decreased osteoclast numbers.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
Researchers have developed a new safety system for CAR-T cells, called VIPER CAR-T cells, that can be turned on or off. This allows doctors to target cancer more aggressively while minimizing side effects. The new system uses an FDA-approved antiviral drug to control the cell's activity.
The PROSPER RCC trial showed no difference in recurrence-free survival between arms, with higher adverse events reported in the nivolumab arm. The trial's results inform future research on neoadjuvant trials in high-risk renal cell carcinoma.
Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients. The three-drug combination showed a 27% lower risk of progression or death compared to the two-drug control, with a median progression-free survival of 11.3 months.
A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
Researchers at Tufts University have developed a novel mRNA-based approach to generate complex antibodies in muscle cells, which can be used to treat various diseases including botulism and cancer. The technique has shown promising results in neutralizing lethal doses of botulinum neurotoxins in mice.
Scientists at UC San Francisco and Gladstone Institutes use CRISPR-based edit to render therapeutic T cells more resilient, overcoming a major factor limiting cancer immunotherapies' success. The discovery may help improve treatment of both solid and liquid tumors.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
Researchers at Cedars-Sinai Cancer identified genetic signatures linked to patient response to immunotherapy in bladder and other cancers. High DDR1 expression is associated with 'cold' tumors, while high DDR2 is linked to 'hot' tumors.
A study from Cold Spring Harbor Laboratory discovered a new list of friendly proteins generated by the human thymus that protects healthy tissue from T cell attacks. This finding may lead to improved treatments for autoimmune disorders such as multiple sclerosis and diabetes.
Researchers used a new 3D imaging technique to analyze the interaction between T-cell therapies and solid mini-tumors, revealing a wide variety of behaviors in engineered T cells. The study identified specific gene signatures of highly potent T cells that can target multiple tumor cells.
Researchers have developed a new quantitative approach to predict and customize site-specific recombination, enabling more efficient genetic and cell therapies. The tool combines high-throughput experiments with machine learning models to control the rate of DNA editing, paving the way for personalized treatment.
Researchers have found a promising new combination therapy that uses immunotherapy alongside a drug blocking a common gene mutation in lung cancer. The study suggests this combination may be effective in 'immune hot' tumours, which are more likely to respond.
A new study uses machine learning models to predict cancer patients' responses to immunotherapy based on their gut microbiome features. The research identifies common gut bacterial taxa associated with responders versus non-responders, providing a potential tool for distinguishing and predicting immunotherapy responders.
Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...
Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.
Researchers at Cleveland Clinic discovered that pathogenic POLE/POLD1 genetic mutations in tumors lead to a high level of immune cell infiltration and improved response to immune checkpoint blockade therapy. The study's findings contribute to the growing list of discoveries that prove certain classes of drugs are more effective based o...
Researchers found specific T-cell populations expanded after immune therapy treatment, predicting which patients would respond best to the treatment. These biomarkers could help select patients for future trials to improve outcomes.
Researchers developed a two-step approach using whole exome sequencing to predict which patients respond to cancer immunotherapy. The study identified six genes, including KRAS and BRAF, that are enriched in patients who responded to treatment.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
Researchers have developed a way to fine-tune CAR T cell therapy to strike a balance between safety and efficacy, reducing the risk of severe side-effects. The new approach enables customisation of potency levels for individual patients, broadening its potential as a first-line treatment.
Researchers discovered that the TCF-1 protein enables plasticity in cells across neighborhoods during T cell development, weakening insulation and increasing interactions between adjacent neighborhoods. This finding sheds new light on immunotherapy approaches and could lead to more efficient cancer treatments.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that infants under 12 months who undergo oral immunotherapy have a better safety profile compared to older preschoolers. The treatment, which involves gradually increasing exposure to peanut flour, is highly effective and safe for this age group.
Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.
Scientists at Max Delbrück Center identify EBAG9 gene as key inhibitor of T cell function against tumors, releasing the brake and boosting immune response. The discovery aims to develop CAR T cells without EBAG9 for more effective leukemia treatments.
Researchers found that 'killer' T-cells used in immunotherapy can also destroy tumour lymphatic vessels, greatly reducing the risk of metastasis. This synergistic effect could increase treatment effectiveness against cancers with high lymphangiogenesis.
A new study found significant racial disparities in receiving immunotherapy for advanced liver cancer, with Black and Hispanic patients having lower access to the treatment. The analysis showed that immunotherapy was more effective than chemotherapy in improving survival rates.
Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.
Researchers at NUS Yong Loo Lin School of Medicine and Xiamen University have developed a novel nanovaccine that achieves complete clearance of solid tumors and induces long-lasting immune memory. The vaccine stimulates anti-tumor immunity by presenting antigens in a way that traditional vaccines cannot.
A recent study published in the New England Journal of Medicine found that dostarlimab was effective in treating a subtype of rectal cancer, showing remarkable responses and resolving difficult symptoms. The treatment offers a more effective and less toxic alternative to traditional chemotherapy and radiation.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
A Phase II study found that immunotherapy before surgery improved median progression-free survival and overall survival for undifferentiated pleomorphic sarcoma and recurrent dedifferentiated liposarcoma patients. The treatment also showed an association between intratumoral B-cell receptor repertoire and survival.
Researchers at Massachusetts General Hospital discovered a novel immunotherapy mechanism that uses CD4+ T helper 2 cells to suppress breast cancer development. These cells force breast cancer cells to revert to benign breast gland cells, providing new insights into the treatment of this disease.
A Phase II clinical trial found that an immunotherapy drug combination extended the lives of patients with non-small cell lung cancer, improving survival by 14.5 months compared to standard care therapy. The treatment also reduced chemotherapy use and side effects.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
Researchers from CiQUS and Karolinska Institutet develop a new immunotherapeutic approach against cancer by blocking adenosine A2B receptors. The study demonstrates that this blockade reactivates the immune system, restoring its effectiveness against tumors.
Researchers found that neoadjuvant immunotherapy with pembrolizumab significantly shrunk tumors in patients with desmoplastic melanoma, potentially allowing for less extensive surgery and radiation. The study showed a high response rate to treatment, with over half of patients achieving a pathologic complete response.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Australian researchers have discovered specific gene networks rewired to drive peanut allergy remission through a combination treatment of probiotic and oral immunotherapy. This network reprogramming shuts down the allergic immune response responsible for causing food allergies.
Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.
Researchers at Massachusetts General Hospital developed two approaches to repair tumor blood vessels, alleviating hypoxia and improving chemotherapy's effectiveness. Combining these approaches may create a more powerful anti-cancer strategy.